Juan E Corral1, Karl F Mareth1, Douglas L Riegert-Johnson1, Ananya Das2, Michael B Wallace3. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida. 2. Center for Digestive Health, St. Joseph's Hospital and Medical Center, Phoenix, Arizona. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida. Electronic address: wallace.michael@mayo.edu.
Abstract
BACKGROUND & AIMS: There have been few studies of abdominal imaging screening of individuals at high risk for pancreatic cancer (based on family history or genetic variants). We performed a meta-analysis of prospective cohort studies to determine the diagnostic yield and outcomes of abdominal imaging screening for asymptomatic individuals at high risk. METHODS: Through a systematic review of multiple electronic databases and conference proceedings through July 2017, we identified prospective cohort studies (>20 patients) of asymptomatic adults determined to be at high-risk of pancreatic cancer (lifetime risk >5%, including specific genetic-associated conditions) who were screened by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) to detect pancreatic lesions. Our primary outcome was identification of high-risk pancreatic lesions (high-grade pancreatic intraepithelial neoplasia, high-grade dysplasia, or adenocarcinoma) at initial screening, and overall incidence during follow up. Summary estimates were reported as incidence rates per 100 patient-years. RESULTS: We identified 19 studies comprising 7085 individuals at high risk for pancreatic cancer; of these, 1660 patients were evaluated by EUS and/or MRI. Fifty-nine high-risk lesions were identified (43 adenocarcinomas: 28 during the initial exam and 15 during follow-up surveillance) and 257 patients underwent pancreatic surgery. Based on our meta-analysis, the overall diagnostic yield screening for high-risk pancreatic lesions was 0.74 (95% CI, 0.33-1.14), with moderate heterogeneity among studies. The number needed to screen to identify 1 patient with a high-risk lesion was 135 (95% CI, 88-303). The diagnostic yield was similar for patients with different genetic features that increased risk, and whether patients were screened by EUS or MRI. CONCLUSIONS: Based on meta-analysis, 135 patients at high-risk for pancreatic cancer must be screened to identify 1 patient with a high-risk pancreatic lesion. Further studies are needed to determine whether screening reduces mortality and is cost effectiveness for individuals at high-risk of pancreatic cancer.
BACKGROUND & AIMS: There have been few studies of abdominal imaging screening of individuals at high risk for pancreatic cancer (based on family history or genetic variants). We performed a meta-analysis of prospective cohort studies to determine the diagnostic yield and outcomes of abdominal imaging screening for asymptomatic individuals at high risk. METHODS: Through a systematic review of multiple electronic databases and conference proceedings through July 2017, we identified prospective cohort studies (>20 patients) of asymptomatic adults determined to be at high-risk of pancreatic cancer (lifetime risk >5%, including specific genetic-associated conditions) who were screened by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) to detect pancreatic lesions. Our primary outcome was identification of high-risk pancreatic lesions (high-grade pancreatic intraepithelial neoplasia, high-grade dysplasia, or adenocarcinoma) at initial screening, and overall incidence during follow up. Summary estimates were reported as incidence rates per 100 patient-years. RESULTS: We identified 19 studies comprising 7085 individuals at high risk for pancreatic cancer; of these, 1660 patients were evaluated by EUS and/or MRI. Fifty-nine high-risk lesions were identified (43 adenocarcinomas: 28 during the initial exam and 15 during follow-up surveillance) and 257 patients underwent pancreatic surgery. Based on our meta-analysis, the overall diagnostic yield screening for high-risk pancreatic lesions was 0.74 (95% CI, 0.33-1.14), with moderate heterogeneity among studies. The number needed to screen to identify 1 patient with a high-risk lesion was 135 (95% CI, 88-303). The diagnostic yield was similar for patients with different genetic features that increased risk, and whether patients were screened by EUS or MRI. CONCLUSIONS: Based on meta-analysis, 135 patients at high-risk for pancreatic cancer must be screened to identify 1 patient with a high-risk pancreatic lesion. Further studies are needed to determine whether screening reduces mortality and is cost effectiveness for individuals at high-risk of pancreatic cancer.
Authors: Naveen M Kulkarni; Lorenzo Mannelli; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Olga R Brook; Elizabeth M Hecht; Fay Kastrinos; Zhen Jane Wang; Erik V Soloff; Parag P Tolat; Guillermo Sangster; Jason Fleming; Eric P Tamm; Avinash R Kambadakone Journal: Abdom Radiol (NY) Date: 2020-03
Authors: Marcia Irene Canto; Tossapol Kerdsirichairat; Charles J Yeo; Ralph H Hruban; Eun Ji Shin; Jose Alejandro Almario; Amanda Blackford; Madeline Ford; Alison P Klein; Ammar A Javed; Anne Marie Lennon; Atif Zaheer; Ihab R Kamel; Elliot K Fishman; Richard Burkhart; Jin He; Martin Makary; Matthew J Weiss; Richard D Schulick; Michael G Goggins; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2019-06-13 Impact factor: 3.452
Authors: Detlef Klaus Bartsch; Elvira Matthäi; Ioannis Mintziras; Christian Bauer; Jens Figiel; Mercede Sina-Boemers; Thomas M Gress; Peter Langer; Emily P Slater Journal: Dtsch Arztebl Int Date: 2021-03-05 Impact factor: 5.594
Authors: Bryson W Katona; Jessica M Long; Nuzhat A Ahmad; Sara Attalla; Angela R Bradbury; Erica L Carpenter; Dana F Clark; Gillain Constantino; Koushik K Das; Susan M Domchek; Christina Dudzik; Jessica Ebrahimzadeh; Gregory G Ginsberg; Jordan Heiman; Michael L Kochman; Kara N Maxwell; Danielle B McKenna; Jacquelyn Powers; Payal D Shah; Kirk J Wangensteen; Anil K Rustgi Journal: Cancer Prev Res (Phila) Date: 2021-08-02